Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Graft rejection and chronic CNI toxicity reduce kidney transplantation success. Oral formulations of tacrolimus such as IR-Tac (immediate release; twice-daily capsules) and PR-Tac (prolonged release; once-daily capsules), exhibit limitations in terms of pharmacokinetics and tolerability, related in part to suboptimal bioavailability. PR-Tac was developed to improve patient adherence to medication and thereby reduce the risk of graft rejection. However, higher drug dosing was seen to be necessary to maintain IR-Tac-equivalent exposure. LCP-Tac is a next-generation, prolonged-release, once-daily tablet that was developed using MeltDose™ technology to increase drug bioavailability, thereby potentially lowering variability in drug absorption and dampening peak-to-trough fluctuations in blood concentration. To test these attributes, we are performing a phase IV, investigator-initiated clinical trial in kidney transplantation.
TaC:Drop (EUCT number: 2023-503531-18-00) compares tacrolimus bioavailability and tests superiority of LCP-Tac (test arm) versus PR-Tac (comparator arm) in kidney transplant recipients treated with a standard immunosuppressive regimen. Patients are randomized 1:1 shortly prior to transplantation surgery; a total of 300 successfully-transplanted patients from 13 transplant centers in Germany will be recruited to the study. After a 12-week Controlled Treatment Phase, whole blood trough levels of tacrolimus are measured in a central clinical laboratory and a dose-normalized trough concentration (C/D ratio) is calculated as an estimate of tacrolimus bioavailability per patient (primary endpoint). Statistically, the trial has been designed with 80 % power to detect a mean C/D ratio difference of 0.5 ng/ml mg-1 using a two group Satterthwaite t-test with a two-sided significance level of 5 %. Secondary descriptive endpoints include the time to reach the first trough level in target range, intra-patient variability in C/D ratio over time, and incidence of graft rejection; other relevant outcomes include eGFR, new onset diabetes after transplantation and tacrolimus-associated neurologic side effects such as e.g. tremor. Clinical parameters are collected annually during a 3-year Follow-up Phase to explore whether a superior C/D ratio can confer longer-term health benefits.
It is projected that recruitment will be completed by the end of 2025, with data collection for the primary endpoint finishing in 2026. After the last study visit in 2028, the final trial analysis will reconcile drug pharmacokinetics with long-term efficacy and safety data.
TaC:Drop is the first prospective, randomized trial in renal transplantation to test if once-daily LCP-Tac immunosuppression improves C/D ratio and thus tacrolimus bioavailability, versus PR-Tac. The trial secondarily tests whether the incidence and severity of renal dysfunction and other tacrolimus-related toxicities are reduced in the cohort assigned to LCP-Tac therapy; this premise is based on previous retrospective research that associates a higher C/D ratio with improved renal function and reduced neurotoxicity.
